

IR BOOK

THE INVESTOR RELATIONS OF CLASSYS 2024
08 MAY 2024

Disclaimer



This material has been prepared by Classys (the “Company”) for the purpose of providing information in a Presentation that will be made for investors. Please be informed that transferring, copying, or re-distributing this document to others is prohibited.

Attendance at this presentation is considered as your agreement to comply with the above-mentioned restrictions, and violation of these restrictions may be regarded as a violation of the Financial Investment Services and Capital Markets Act of Korea.

The forward-looking statements included herein are unverified and pertains to future events related to the Company’s expected future financial performance, and are expressed with words such as ‘forecast,’ ‘prospect,’ ‘plan,’ ‘expectation,’ ‘outlook’ and ‘(E).’

The above forward-looking statements are subject to changes in future business environments and inherently contain uncertainty. Due to this uncertainty, actual future performance may significantly differ from the information stated or implied in the forward-looking statements.

Additionally, the future outlook is based on the information available at the time of the presentation and is subject to change based on future market developments and changes in the Company’s strategic direction without separate notice.

The Company and its executives do not assume any responsibility for losses incurred through the use of this document (including negligence and other cases).

This document does not constitute a solicitation for placement, sales, trading or subscription of stocks. No part of this document should be considered as a basis or ground for related contracts, agreements, or investment decisions. All investment decisions related to stock purchases should be made solely based on investors’ reasonable judgment.



Contents

I . Basic Understanding of Classys

1. Business Philosophy
2. Differentiated Model
3. Main Product_Ultraformer MPT
4. Main Product_Volnewmer

II . Company Overview

1. Key Figures
2. Corporate Information
3. Product Portfolio
4. Market Portfolio
5. ESG

III. Business Highlights

1. Classys' Success Formula
2. Installed base Increase and Rapid Consumable Sales
3. Unrivaled Presence in Domestic HIFU Market
4. Strong Global Presence in Major Countries
5. Accelerate the Sales of Monopolar RF, Volnewmer

IV. Growth Strategy

1. EBD, Growth Engine of Medical Aesthetic Market
2. Global Approval Expansion
3. Tier-up Strategy in Each Country
4. Innovative Technology Diversification
5. Specialized B2B & B2C Marketing
6. Quality / Production Advancement
7. Classys Expansion Plan

V . Financial Results

1. 1Q24 Earnings
2. 2024 Guidance
3. Quarterly Performance Trends
4. Annually Performance Trends

Basic Understanding of Classys

CLASSYS

Cluederm


shurink® / SKEDERM

1. Business Philosophy
2. Differentiated Model
3. Main Product_Ultraformer MPT
4. Main Product_Volnewmer

1. Business Philosophy

Delivering innovative products & solutions that address customers' unmet needs and pain points for healthy, natural beauty

Well-aging Trend Acceleration



Classys' innovative products drive market growth through enhanced accessibility


- User/Patient-centric innovation: Pioneered by Classys' Dermatologist Founder
- Management Excellence: Crafting a Customer-Focused Innovation Ecosystem (incorporating CIC* & VoC)

* CIC: Customer Innovation Center

Unmet needs




Pain points




2. Differentiated Model

Poised to become a global aesthetic business leader based on an established a sustainable growth business model

As-is




Classys



Sustainable Growth Business Model

Expanding into over 70 countries, with advances into Europe, the U.S., and China anticipated



* KSF: Key Success Factors


ULTRAFORMER MPT



Ultraformer MPT (Shurink Universe) | HIFU

* HIFU(High Intensity Focused Ultrasound): Eyebrow lifting, facial/abdominal/thigh lifting, abdominal circumference reduction

Mechanism of Action



Upper dermis(1.5mm)
Lower dermis(3.0mm)
SMAS layer(4.5mm)

Delivering
ultrasound energy
non-invasively to
target skin layers

Heating the
focal skin tissues
to the optimal
temperature for
collagen contraction
and denaturation

The collagen
contraction results in
skin lifting effect.

Features

7 Cartridges for Different Depths

ULTRA F handpiece-exclusive 4 cartridges



DERMA 1.5mm I 2.0mm CELUP 3.0mm LINUP 4.5mm

3 pen-type cartridges exclusively for ULTRA BOOSTER handpieces



DERMA 1.5mm CELUP 3.0mm LINUP 4.5mm


Cartridge tips can easily follow skin curves, enabling delicate procedures

MP & Normal (Dot)



Normal Mode


MP Mode



Normal Mode

MP Mode

Less Pain, Faster Results



Previous
One way procedure

New
Two-way procedure

Procedure Durations (for 300 shots)

..... About 8~10 min.



Normal mode
Ultraformer III

MP mode
Ultraformer MPT

* This slide is prepared to assist the understanding of investors, and for further details, please refer to the MFDS approval requirements and product description.



Volnewmer | 6.78MHz Monopolar RF

* RF (Radio Frequency): Induces tightening of dermis & production of collagen

Mechanism of Action



Monopolar RF coagulates skin

6.78MHz RF current is converted into thermal energy when applied to the target skin surface.


Thermal damage causes skin tissue coagulation.

As the coagulated tissue recovers, the effects begin right after the procedure and are sustained.

Features


4 tips of different sizes

Four different tip shapes applicable according to the target area




Continuous Water Cooling

Continuous water cooling can simultaneously protect the skin surface and transfer more intense thermal energy.



Strong & Safe Energy Transfer

Tiltable & cushion-equipped hidden edge tip design effectively transfers RF energy.



* This slide is prepared to assist the understanding of investors, and for further details, please refer to the MFDS approval requirements and product description.



Company Overview



Cluederm

shurink[®] / SKEDERM

1. Key Figures
2. Corporate Information
3. Product Portfolio
4. Market Portfolio
5. ESG

1. Key Figures

Sales Growth

5Y CAGR **31%**

(as of 2023 KRW 180.2bn, YoY +27%)

Consumable Sales Growth

5Y CAGR **39%**

(as of 2023 KRW 81.0bn, YoY +46%
consumables portion 45%)

EBITDA Growth

5Y CAGR **39%**

(as of 2023 EBITDA KRW 93.7bn, YoY +29%
EBITDA Margin 52%)

* 5Y = 2018~2023

Overseas Sales

65% (as of 2023)

Export to 70 countries /
Secured approvals in 29 countries

Global Installed base / annual cases of procedures

Over **15K units**
4M cases

* Based on Global Ultraformer Series

Valuation

Market cap **KRW 2+ tril**

Listed on KOSDAQ's Global Segment
ESG Rating BBB (by MSCI)





2. Corporate Information

In 2022, Classsys enhanced its corporate structure by onboarding ten new executives with diverse expertise. We also introduced two new entities and promoted the Marketing Division to better support our CEO.

Company Overview

Company name	CLASSSYS Inc.
CEO	Baek, Seung-han
Date incorporated	10 January 2007
Date listed	28 December 2017
Equity capital	KRW 6,477 M (as of the end of March 2024)
Headcount	391 persons (as of the end of March 2024)
Business area	Manufacturing of medical aesthetics devices & distribution of cosmetics
Brands	 CLASSSYS Cluederm shurink / SKEDERM
HO address	CLASSSYS, 208, Teheran-ro, Gangnam-gu, Seoul, Korea
Website/e-mail.	http://www.classsys.com / ir@classsys.com

Shareholder & Management Structure



* As of the end of March 2024

* In March 2024, all held treasury stocks were retired; the current total issued shares are 63,999,519.

3. Product Portfolio



Cluederm

Ulfit
Eyebrow lifting, improve elasticity in face, abdomen, thigh HIFU

Cartridges

Aquasure
aspirating blood, body fluid and pimple + causing absorption of medicine

Solution

Refit
alleviate pain RF

RF Lotion




Scizer
Reduce abdominal circumference HIFU

Cartridges

Clatuu Alpha
Cooling control technology for reduce subcutaneous layer

Zel-pad



Ultraformer III (Shurink)
Eyebrow lifting, improve elasticity in face, abdomen, thigh and remove wrinkles HIFU¹⁾

Cartridges

Ultraformer MPT (Shurink Universe)
Gen. 2 Shurink
- MP & Normal modes
- Ultra Booster cartridge added

Cartridges

Volnewmer
6.78MHz monopolar RF²⁾ causing tissue coagulation

Tips


1. HIFU (High Intensity Focused Ultrasound): Eyebrow lifting, facial/abdominal/thigh lifting, abdominal circumference reduction;
2. RF (Radio Frequency): Induces tightening of dermis & production of collagen;

* As of 2023

4. Market Portfolio


Sales Portion by Region

(Unit: KRW Billion)



Sales by Country

(Unit: KRW Billion)



* Brazil, Thailand, CIS, Japan, Hong Kong, Australia, Taiwan, Indonesia, Spain, Mexico




5. ESG

ESG Ratings

ESG Report

Classsys 2023 Sustainability Report

Classsys transparently discloses its performance results in its pursuit of a sustainable future.



ESG Strategic Tasks



- Activities for greenhouse gas and energy reduction
- Operation of EHS team for environmental management compliance
- Environmental management education and incorporation of performance results into the remuneration scheme
- Refurbishment process for product waste reduction



- Talent Management: Fair recruitment and rational personnel evaluation system improvement and stabilization
- Human Rights Management: Strengthening human rights education and employee grievances channel: Helpyou, Withyou
- Information Security: Establishing a systematic information security infrastructure
- SCM: supply chain due diligence & support



- Accountable management by a professional and independent board of directors- Compensation Committee, Candidate Recommendation Committee, Outside Director Council
- Shareholder-friendly policies and shareholder return policy
- Ethical and legal compliance management, Anti-corruption programs
- Company-wide integrated approach to risk management



Cluederm


shurink[®] / SKEDERM

Business Highlights

1. Classys' Success Formula
2. Installed base Increase and Rapid Consumable Sales
3. Unrivaled Presence in Domestic HIFU Market
4. Strong Global Presence in Major Countries
5. Accelerate the Sales of Monopolar RF, Volnewmer

1. Classys' Success Formula

Established a virtuous cycle of 'launching an innovative product → Increased sales of consumables in tandem with the use of installed devices → global sales growth'




2. Installed base Increase and Rapid Consumable Sales

Accelerate growth, expanding into global market after popularizing Ultraformer III (Shurink) in Korea

Domestic Installed base and Consumable Sales

(1K units, KRW billion, %)




Launching Innovative Product, Shurink

Launching Generation 2, Shurink Universe

Global Installed base and Consumable Sales

(1K units, KRW billion, %)



Launching Ultraformer III


Launch of Ultraformer III In Brazil

Launching Ultraformer MPT

3. Unrivaled Presence in Domestic HIFU market

5,300+ units sold accumulatively, securing unrivaled No.1 position in the domestic HIFU market

55% M/S in Domestic HIFU Market



- Shurink's accumulated sales : 3,700+ units
- Shurink Universe's accumulated sales : 1,600+ units

Shurink launched in 2014 and Shurink Universe in 2022

B2B Customers

+3,000 Shurink-equipped clinics in Korea

- **Over 90%** of 600 large-network clinics using Shurink
- **User-generated marketing content** promotion of the procedures (doctors' YouTube channels, blogs)
- **Most preferred device** by doctors newly entering the medical aesthetics sector
- An **"Essential" device** for the dermatology/plastic surgery clinics and aesthetics-specialized clinics



B2C Customers

Domestically 1.2M Shurink procedure cases per year (E)


- An overwhelming volume of **viral review postings** by end users
- **Digital buzz No.1** among medical aesthetics device brands (SNS, blog, beauty app)
- **#Shurink over 146K vs.** #foreign brand A 99K, #local brand B 9K, #local brand C 6K




4. Strong Global Presence in Major Countries

Anticipated market expansion and increased consumable sales growth in Brazil and Thailand

Sales Trend in Brazil



Sales Trend in Thailand



Two-track Approach



• Ultraformer MPT

- Targets to secure the premium market position by being renowned as **the most reliable procedure**

• Ultraformer III

- Positioning itself **as an essential tool** for dermatologists in private practice, aiming for mainstream popularity



Marketing Campaigns

• B2B Marketing

- local Ultraformer specialist clinical teams offer skilled know-how to doctors, helping maximize the efficacy and efficiency of procedures
- Evidence-based User Meetings and Product Launch Symposiums

• B2C Marketing

Expanding the Classsys/Ultraformer brand presence through online social media platforms

Market with High Growth Potential


• **Unmatched scales**, compared to the domestic market, in the number of dermatologist clinics, doctors, and end users

• **Customer base is growing faster** with age diversification, increased male participation, and an increase in the utilization rate of cosmetic products

• **With the launch of Volnewmer, a Volformer marketing plan is promoting** combined procedures involving Volnewmer and Ultraformer

5. Accelerate the Sales of Monopolar RF (Volnewmer)

Creating a virtuous cycle of innovative new RF device, Volnewmer



Growth Strategy


1. EBD, Growth Engine of Medical Aesthetic Market
2. Global Approval Expansion
3. Tier-up Strategy in Each Country
4. Innovative Technology Diversification
5. Specialized B2B & B2C Marketing
6. Quality / Production Advancement
7. Classys Expansion Plan

1. EBD, Growth Engine of Medical Aesthetic Market

EBD procedures have become more common, procedure trend will be rapidly grew by CLASSYS Product

Global EBD Market Growth Outlook

(Unit: USD Million)




1) EBD (energy based device): a device regenerating skin condition & elasticity with non-invasive energy stimulation without surgical procedures

* Source: ASAPS, Gallup Korea, Markets and markets, Mordor Intelligence


Non-invasive Aesthetics Procedure Cases in USA

(Unit: 1M cases)



Medical Beauty Penetration rate by Countries

Legend: 2014 (light blue), 2019 (medium blue), 2022 (dark blue)



Habituation

- **Aesthetics procedures have become routines** of everyday life such as job interviews, weddings, and more.
- **Preference for non-invasive procedures**, such as EBD procedures, that leave no marks and require minimal recovery time

Popularization

- **High revisit rate** by satisfied consumers
- No longer a luxury reserved for the affluent but **an essential part of self-grooming**
- **More affordable and accessible** aesthetic procedures compared to plastic surgery

Source: Qianzhan Industrial Research Institute, China Baogao, Nomura research

2. Global Approval Expansion

Ultraformer MPT/Volnewmer will expand into major markets, including Europe, the USA, and China

Global Expansion Roadmap




11,000+ Units Sold Globally

Export to 70 countries
(Secured approvals in 29 countries)

TOP 10 best-selling countries


- Brazil
- Thailand
- CIS
- Japan
- Hong Kong
- Australia
- Taiwan
- Indonesia
- Spain
- Mexico



3. Tier-up Strategy in Each Country

Proactively support key markets with customized Tier-up strategies

Country Outlook by Tier



Tier-up Strategy


- Tier 1**
 Annual sales > KRW 10 bn
 - Marketing Maximize sales with localized B2B
 - Strengthen Volformer Marketing
 - Brazil, Japan, Thailand, CIS
- Tier 2**
 Annual sales > KRW 5~10 bn
 - Benchmark Tier-1's success cases
 - Replacing the Ultraformer MPT trend and promoting on procedures
 - Launch Volnewmer in strategic priority regions
 - Australia, Hong Kong, Taiwan
- Tier 3**
 Annual sales > KRW 1~5 bn
 - Accelerating the sales of Ultraformer equipment to raise our brand awareness in the EBD market
 - Launch Ultraformer MPT for Premium Market
 - Europe, Indonesia, UAE
- Tier 4**
 Annual sales < KRW 1 Bn
 - Boost-up approach to high potential countries

4. Innovative Technology Diversification

Develop Innovative Product Addressing the Unmet Needs of Customers based on differentiated R&D organization & competence


R&D Expenses

(Unit: KRW Billion)




R&D Experts

(Unit: persons)




Number of IPs Registered



* 35% R&D Division of managerial employees (As end of Sep, '23)

Detailed Technology Roadmap Encompassing the Entire Spectrum of EBD Technology



5. Specialized B2B & B2C Marketing

Marketing Virtuous Cycle Process with Experts and the Public to maximize treatment of HIFU and RF

B2B Marketing

Diversifying face-to-face contacts by domestic/overseas region

Classys Ambassadors



Domestic/Global Classys Ambassadors (key doctors)
~30 persons

Scientific Evidence



Ultraformer MPT, Volnewmer
~10 papers including SCI(E) level

Classys Academy & User Meetings



User meetings & conferences by global region
+10 countries ~20 times

Domestic/Global Conferences/Seminars




Medical conferences & key doctor lectures
~20 times


B2C Marketing

Maximizing our brand exposure by working with multiple popular celebrities

Working with powerful celebrity models



Volnewmer models:
Actresses Lim Ji-yeon & Cha Joo-young




Shurink model:
Actress Koh Min-see

All-out marketing campaigns on all available channels



6. Quality / Production Advancement

Innovate manufacturing processes/sites to secure world's top-tier production and quality competence



Production Planning

- Establishing demand forecasting-based production processes through **S&OP meetings** (Sales and Operations Plan)
- Establishing **optimal inventory standards** to minimize excess inventory and enhancing market demand responsiveness
- Improving accuracy of sales forecast to ensure on-time delivery & **minimize obsolete stock**



Operation Control

- Establishing '**Lean**' production system & continuous-flow processes
- Enhancing productivity through digital Operations
- Innovating labor-intensive processes **with factory automation robots** (higher efficiency)



Quality Management

- Securing globally competitive product quality by improving QMS
- Adopting **P-FMEA** (Process-Failure Mode Effect Analysis) to reduce defects in manufacturing processes and minimize quality issues
- Addressing quality non-conformances **via Corrective Action/Preventive Action activities**

7. CLASSYS Expansion Plan

“A global aesthetics business leader”
 delivering customer-oriented and innovative products and solutions





Cluederm

shurink[®] / SKEDERM

Financial Results

1. 1Q24 Earnings
2. 2024 Guidance
3. Quarterly Performance Trends
4. Annually Performance Trends

1. 1Q24 Earnings _ Profit & Loss

(Unit: KRW Billion)

	1Q24	1Q23	YoY	4Q23	QoQ
Revenue	50.4	39.0	+29.3%	47.0	+7.2%
COGS	10.2	8.8	+16.1%	10.1	+0.8%
(%)	20.2%	22.5%	-2.3%p	21.5%	-1.3%p
Gross profit	40.2	30.2	+33.1%	36.9	+8.9%
(%)	79.8%	77.5%	+2.3%p	78.5%	+1.3%p
SG&A	13.7	10.3	+32.7%	15.0	-8.6%
(%)	27.2%	26.5%	+0.7%p	31.9%	-4.7%p
Operating profit	26.5	19.9	+33.3%	21.9	+20.9%
(%)	52.6%	51.0%	+1.6%p	46.6%	+6.0%p
Financial Income	6.5	4.4	+47.6%	(1.9)	-450.5%
Financial Expenses	0.6	1.1	-51.4%	1.4	-60.1%
Other Income	0.0	0.0	-60.0%	0.0	-97.6%
Other Expenses	0.3	0.0	+3045.5%	0.4	-13.1%
Net Income before Income Tax	32.1	23.1	+38.7%	18.3	+75.4%
Income Tax	6.0	4.4	+37.8%	2.6	+131.1%
Net Income	26.1	18.8	+39.0%	15.7	+66.2%
(%)	51.8%	48.2%	+3.6%p	33.4%	+18.4%p
EBITDA	27.6	20.9	+32.5%	23.1	+19.9%
(%)	54.9%	53.6%	+1.4%p	49.1%	+5.8%p

> Revenue: KRW 50.4 bn (YoY +29.3%, QoQ +7.2%)

- Record-high quarterly revenue achieved
- Increase in overseas consumables sales drove revenue growth in Q1 2024

> GPM: 79.8% (YoY +2.3%p, QoQ +1.3%p)

- COGS ratio improved due to a higher share of consumables sales (up 4.7%p YoY to 52.7% in Q1 2024)
- Cost efficiency achieved through maintaining appropriate pricing post-new product launch and lean production management

> OPM: 52.6% (YoY +1.6%p, QoQ +6.0%p)

- Record-high quarterly operating income achieved
- YoY growth in salaries, R&D, and advertisement, but % of revenue stabilized
- Reduction in one-off expenses (commissions) from Q4 2023

> NI: KRW 26.1 bn (YoY +39.0%, QoQ +66.2%)

- Financial income/expenses fluctuate with exchange rate changes

> EBITDA Margin: 54.9% (YoY +1.4%p, QoQ +5.8%p)

1. 1Q24 Earnings – Sales by Brand

(Unit: KRW Billion)

	1Q24	1Q23	YoY	4Q23	QoQ
CLASSYS (Medical Devices)	20.8	18.4	13.3%	23.8	-12.8%
Export	14.3	12.5	14.5%	16.6	-14.1%
Domestic	6.5	5.9	10.9%	7.2	-9.7%
CLUEDERM (Aesthetics Devices)	1.4	1.2	20.7%	1.5	-6.7%
Export	1.3	1.0	28.6%	1.5	-10.8%
Domestic	0.1	0.1	-44.4%	0.01	677.8%
Consumables	26.5	18.7	42.0%	20.1	32.1%
Export	17.3	10.5	65.5%	11.6	49.1%
Domestic	9.1	8.2	11.3%	8.5	8.1%
shurink®/SKEDERM (Homecare products)	1.4	0.3	404.3%	1.3	9.5%
Export	0.7	0.1	997.3%	1.0	-28.8%
Domestic	0.7	0.2	227.2%	0.3	139.2%
Rentals	0.3	0.5	-40.5%	0.3	1.4%
Total	50.4	39.0	29.3%	47.0	7.2%
Export	33.6	24.0	40.0%	30.7	9.5%
Domestic	16.7	14.9	12.1%	16.3	2.8%

> CLASSYS: KRW 20.8 bn / 41% of Revenue

- Exports Steady yoy sales growth from new products— Ultraformer MPT (Shurink Universe) and Volnewmer
- Domestic: Stable sales performance for Shurink Universe and Volnewmer
- Sales expected to increase in Q2 after equipment inventory depletes and seasonality

> CLUEDERM: KRW 1.4 bn / 3% of Revenue

> Consumables: KRW 26.5 bn / 53% of Revenue

- Exports: Rapid expansion of HIFU procedures in 2023, led by Ultraformer MPT installed in key markets - Notably high sales growth of consumables in Brazil, Thailand
- Domestic: Continuing growth for 8 consecutive quarters due to expanding Shurink Universe procedures

> Shurink RX/SKEDERM: KRW 1.4 bn / 3% of Revenue

- Exports: Sales growth in lifting patches destined for China
- Domestic: Increase in new device sales following the domestic launch of Volium in January 2024

> Rentals: KRW 0.3 bn / 1% of Revenue

1. 1Q24 Earnings _ SG&A

(Unit: KRW Billion)

	1Q24	1Q23	YoY	4Q23	QoQ
Salaries	2.7	2.2	+25.0%	2.5	+9.9%
(% of sales)	5.5%	5.6%		5.3%	
R&D	2.8	2.1	+32.3%	2.6	+8.1%
(% of sales)	5.6%	5.4%		5.5%	
Advertisement	2.2	1.3	+68.9%	2.5	-12.4%
(% of sales)	4.4%	3.4%		5.4%	
Commissions	1.7	1.8	-4.1%	2.7	-37.4%
(% of sales)	3.3%	4.5%		5.8%	
Sales commission	0.8	0.6	+38.4%	0.9	-6.5%
(% of sales)	1.6%	1.5%		1.8%	
Depreciation/Amortization	0.6	0.5	+31.7%	0.6	+4.4%
(% of sales)	1.1%	1.1%		1.2%	
Employee benefits	0.3	0.2	+19.5%	0.5	-49.0%
(% of sales)	0.6%	0.6%		1.2%	
Warranty expenses	0.1	0.1	+105.4%	0.4	-64.2%
(% of sales)	0.3%	0.2%		0.8%	
Others	2.4	1.6	+52.6%	2.3	+4.7%
(% of sales)	4.8%	4.1%		5.0%	
Total	13.7	10.3	+32.7%	15.0	-8.6%
(% of sales)	27.2%	26.5%		31.9%	

> Salaries: KRW 2.7 bn / 5.5% of Revenue
(YoY +25.0%, QoQ +9.9%)

> R&D: KRW 2.8 bn / 5.6% of Revenue
(YoY +32.3%, QoQ +8.1%)

- Acceleration of new product development and increased staffing to gain approvals/licensing in more countries
- Costs related to licensing in the USA and China are being capitalized (KRW 0.9 bn in 2023, KRW 1.2 bn in Q1 2024)

> Advertisement: KRW 2.2 bn / 4.4% of Revenue
(YoY +68.9%, QoQ -12.4%)

- Reinforcing domestic KOL networks and enhancing B2B marketing with evidence-based messaging
- Expanding B2B marketing, including new product launch symposia and user meetings in foreign countries

> Commissions paid: KRW 1.7 bn / 3.4% of Revenue
(YoY -4.1%, QoQ -37.4%)

- QoQ reduction in one-off expenses (consultancy fees for equity investment) from Q4 2023

> Sales Commissions: KRW 800 mn / 1.6% of Revenue
(YoY +38.4%, QoQ -6.5%)

- Commissions linked to domestic equipment sales of Shurink Universe and Volnewmer

1. 1Q24 Earnings – Financial Status

(Unit: KRW Billion)

	2021	2022	2023	1Q24
Assets				
Current assets	73.1	147.8	185.7	212.6
Cash & cash equivalents				
Sort-Term Financial Instruments	47.9	111.6	136.9	157.3
Fair Value Through Profit or Loss				
Inventories	16.5	23.4	19.4	19.4
Accounts receivables and Other Receivables	2.1	8.0	17.7	24.0
Non-current assets	143.2	183.6	189.7	190.3
P.P.E.	80.7	104.2	139.0	143.5
Invested properties	58.4	74.7	41.1	36.3
Total Assets	216.3	331.4	375.4	402.9
Liabilities				
Current liabilities	16.8	36.2	29.2	105.0
Non-current liabilities	35.8	65.6	62.7	0.6
Total Liabilities	52.6	101.8	91.9	105.6
Equity				
Retained earnings	133.1	204.2	271.0	264.3
Total Equity	163.7	229.6	283.5	297.2
Total Liabilities + Equity	216.3	331.4	375.4	402.9

> **Current Ratio: 202%, Debt Ratio: 36%**

> **Current Assets: KRW 212.6 bn**

- Cash & cash equivalents, up KRW 20.4 bn YoY due to strong sales performance
- Inventories maintained at an appropriate level
- Accounts receivable breakdown: 12% in domestic, 88% in exports
 - 96% of domestic AR is recoverable within 3 months
 - 67% of export AR is attributable to key market and recoverable within 6 months as consumables orders follow equipment purchases

> **Non-current Assets: KRW 190.3 bn**

- PPE (self-use) KRW 143.5 bn, investment property (for lease) KRW 36.3 bn
- Growing proportion of self-use due to the expiration of lease terms for some lots of the head office building

> **Current Liabilities: KRW 10.5 bn**

- Short-term borrowings: KRW 63.8 bn (reclassified based on remaining maturity)
- Current tax liabilities: KRW 11.9 bn


> **Non-current Liabilities: KRW 0.6 bn**

> **Equity: KRW 297.2 bn**


2. 2024 Guidance



3. Quarterly Performance Trends(1)





Note 1) On a consolidated basis



Note 1) On a consolidated basis

3. Quarterly Performance Trends(2)




Note 1) On a consolidated basis


Note 2) ₩/\$ exchange rate is averaged over the period.

w/\$

4. Annually Performance Trends(1)




Note1) On a consolidated basis






Note1) On a consolidated basis

4. Annually Performance Trends(2)

CLASSYS CLUEDERM Consumables shurink/SKEDERM Rentals (Unit: KRW Billion)



Domestic Export (Unit: KRW Billion)



1,053	1,132	1,160	1,130	1,101	1,166	1,180	1,144	1,292	1,305
-------	-------	-------	-------	-------	-------	-------	-------	-------	-------

W/\$

Note 1) On a consolidated basis

Note 2) W/\$ exchange rate is averaged over the period.

Note 1) On a consolidated basis



Classys, 208, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea

<http://www.classys.com> | +82-2-6313-2106

email : ir@classys.com

IROODA Strategy

Strengthening our global presence through active partnerships and collaborations

